← Back to headlines
Gilead Sciences to Acquire Arcellx in Strategic Move
Gilead Sciences is reportedly set to acquire Arcellx, a move that would expand Gilead's portfolio and strategic capabilities within the biopharmaceutical sector.
27 Apr, 06:04 — 27 Apr, 06:04
Sources
Showing 1 of 1 sources
